Advisors Asset Management Inc. Lowers Stake in Solventum Corporation $SOLV

Advisors Asset Management Inc. cut its holdings in Solventum Corporation (NYSE:SOLV) by 72.2% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,290 shares of the company’s stock after selling 16,351 shares during the quarter. Advisors Asset Management Inc.’s holdings in Solventum were worth $477,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the business. Strengthening Families & Communities LLC grew its holdings in shares of Solventum by 376.8% during the first quarter. Strengthening Families & Communities LLC now owns 329 shares of the company’s stock worth $25,000 after buying an additional 260 shares during the last quarter. Barrett & Company Inc. lifted its position in Solventum by 206.2% during the 2nd quarter. Barrett & Company Inc. now owns 398 shares of the company’s stock worth $30,000 after acquiring an additional 268 shares during the period. IMG Wealth Management Inc. acquired a new stake in Solventum during the 2nd quarter worth approximately $31,000. Smartleaf Asset Management LLC grew its stake in shares of Solventum by 193.4% in the 1st quarter. Smartleaf Asset Management LLC now owns 534 shares of the company’s stock valued at $40,000 after purchasing an additional 352 shares during the last quarter. Finally, MTM Investment Management LLC acquired a new position in shares of Solventum in the second quarter valued at approximately $40,000.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Wells Fargo & Company increased their price target on Solventum from $79.00 to $82.00 and gave the stock an “equal weight” rating in a report on Monday, September 15th. BTIG Research upgraded shares of Solventum from a “neutral” rating to a “buy” rating and set a $100.00 target price for the company in a research note on Tuesday. Piper Sandler lifted their target price on shares of Solventum from $94.00 to $98.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Wall Street Zen lowered shares of Solventum from a “buy” rating to a “hold” rating in a research note on Monday. Finally, Zacks Research upgraded shares of Solventum from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Solventum has an average rating of “Hold” and a consensus price target of $87.00.

Solventum Stock Up 0.1%

SOLV stock opened at $85.61 on Wednesday. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.50 and a quick ratio of 1.14. The company’s 50 day simple moving average is $74.25 and its 200-day simple moving average is $73.83. Solventum Corporation has a 12 month low of $60.70 and a 12 month high of $88.20. The firm has a market capitalization of $14.85 billion, a PE ratio of 9.86, a P/E/G ratio of 9.03 and a beta of 0.26.

Solventum (NYSE:SOLV) last posted its earnings results on Thursday, November 6th. The company reported $1.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.43 by $0.07. The firm had revenue of $2.10 billion for the quarter, compared to analyst estimates of $2.05 billion. Solventum had a return on equity of 28.01% and a net margin of 18.13%.Solventum’s revenue was up .7% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.64 EPS. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. Equities analysts expect that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Solventum announced that its board has approved a share repurchase program on Thursday, November 20th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the company to buy up to 7.5% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s management believes its stock is undervalued.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.